Safety of Live-Attenuated Measles, Mumps, and Rubella Vaccine Administered Within 2 Years of Hematopoietic Cell Transplant.

Michaël DesjardinsXhoi MitreAmy C ShermanStephen R WalshMatthew P ChengSanjat KanjilalVincent T HoLindsey R BadenNicolas C Issa

Published in: Open forum infectious diseases (2021)

MMR vaccine appears to be well tolerated in select HCT recipients when given between 300 and 729 days after transplant. An uncomplicated case of vaccine-associated rubella illness was seen after vaccination. Assessment of potential risks and benefits of MMR vaccination given within 2 years of HCT remains important.

Keyphrases

human health
bone marrow
single cell
cell therapy
cell cycle arrest
mesenchymal stem cells
climate change
cell proliferation